Daraxonrasib Doubles Survival for Pancreatic Cancer

A groundbreaking new pill, Daraxonrasib, is rewriting the odds for pancreatic cancer patients—those who’ve run out of options are now living more than double their previous survival window, with a 60% drop in death risk. Once given just six months to live, patients are now surviving over a year thanks to this targeted therapy that attacks cancer’s growth engine. With 68,000 Americans expected to be diagnosed this year, this breakthrough offers rare hope in a disease notoriously hard to catch early. Doctors call it one of the most promising advances in decades—and researchers are already turning attention to early detection to stop cancer before it starts. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4a798e56d540594c